J2277 Motixafortide - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Motixafortide

Brand Name:

Motixafortide

Strength:

0.25mg

HCPCS:

J2277

SEER*Rx Category:

Ancillary Therapy

Major Drug Class:

Immunostimulant

Minor Drug Class:

Stem cell mobilizer

Oral (Y/N):

No

FDA Approval Year:

2023

FDA Discontinuation Year:

CMS Effective Date:

April 17, 2024

CMS Discontinuation Date:

Status:

In Use